Fig. 3From: HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC resultsTreatment outcome according to HER2/CEP17 ratio. A Progression-free survival according to HER2/CEP17 ratio (n = 78). B Overall survival according to HER2/CEP17 ratio (n = 78)Back to article page